Who is sponsoring NCT04206787?

NCT04206787 is sponsored by Boehringer Ingelheim.

What condition does NCT04206787 study?

NCT04206787 studies Non-squamous, Non-Small Cell Lung Cancer.

What is the status of NCT04206787?

NCT04206787 is currently COMPLETED.

Last reviewed 2025-02-28 · How we verify

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

NCT04206787 COMPLETED Results posted

This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC. Furthermore, this study can also assess the effectiveness and safety of afatinib as first-line treatment.

Details

Lead sponsor	Boehringer Ingelheim
Status	COMPLETED
Enrolment	72
Start date	Wed May 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

Afatinib

Countries

China